360
Participants
Start Date
December 31, 2005
Primary Completion Date
January 31, 2009
Study Completion Date
July 31, 2009
Defibrotide
Defibrotide 25 mg/kg/d
Defibrotide
Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
Defibrotide
Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
University Hospital, Graz
St Anna Kinderspital, Vienna
Inst. Gustave Roussy, Villejuif
University Hospital, Dresden
Klinik Kinder-Onkologie, Düsseldorf
Johann-Wolfgang Goethe Universität, Frankfurt
Universitätsspital Eppendorf, Hamburg
Medical School, Hanover
University Hospital, Heidelberg
Kinderklinik, Jena
Christian-Albrecht -University, Kiel
Kinderpoliklinik Uni, München
Poliklinik Kinderheilkunde, Münster
Universitätsspital, Tübingen
Our Lady's Hospital for Sick Children, Dublin
Schneider Children's MC, Petah Tikva
Institute G. Gaslini, Genova
Ospedale S. Gerardo, Monza
Clinica di Oncoematologia Pediatrica, Padua
University Hospital, Utrecht
Sahlgrenska University Hospital, Gothenburg
University Hospital, Huddinge
University Hospital, Lund
University Hospital, Uppsala
University Children Hospital, Basel
Inselspital, Bern
Hopital Cantonal Universitaire, Geneva
University Hospital, Zurich
Great Ormond Street Hospital, London
Children's Hospital, Manchester
Collaborators (1)
Jazz Pharmaceuticals
INDUSTRY
Deutsche Krebshilfe e.V., Bonn (Germany)
OTHER
European Society for Blood and Marrow Transplantation
NETWORK